CLGN
CollPlant Biotechnologies Ltd.NASDAQHealthcare$0.53-16.64%ClosedMarket Cap: $6.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.93
P/S
2.38
EV/EBITDA
-0.25
DCF Value
$-2.32
FCF Yield
-172.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
26.3%
Operating Margin
-484.3%
Net Margin
-484.6%
ROE
-114.1%
ROA
-106.5%
ROIC
-128.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $60.0K | -580.0% | $-3.1M | $-3.2M | $-0.25 | — |
| FY 2025 | $2.4M | 26.3% | $-11.5M | $-11.5M | $-0.94 | — |
| Q3 2025 | $77.0K | -539.0% | $-3.5M | $-3.5M | $-0.27 | — |
| Q2 2025 | $179.0K | -131.8% | $-3.2M | $-3.3M | $-0.28 | — |
| Q1 2025 | $2.1M | 79.0% | $-1.6M | $-1.5M | $-0.13 | — |
| Q4 2024 | $164.0K | -213.4% | $-4.0M | $-3.9M | $-0.34 | — |
| FY 2024 | $515.0K | -417.1% | $-17.3M | $-16.6M | $-1.45 | — |
| Q3 2024 | $4.0K | -13075.0% | $-4.5M | $-4.3M | $-0.38 | — |
| Q2 2024 | $249.0K | -220.1% | $-4.4M | $-4.2M | $-0.37 | — |
| Q1 2024 | $98.0K | -741.8% | $-4.3M | $-4.2M | $-0.37 | — |
| Q4 2023 | $299.0K | -253.5% | $-5.1M | $-4.7M | $-0.41 | — |
| FY 2023 | $11.0M | 71.8% | $-7.5M | $-7.0M | $-0.62 | — |